In a 68-year-old woman with malignancy-associated hypercalcemia refractory to aggressive intravenous saline, loop diuretics, and a full dose of denosumab, and with renal insufficiency (serum creatinine 3.4 mg/dL, estimated creatinine clearance ≈15‑20 mL/min), what is the next appropriate treatment option?

Hemodialysis with Low-Calcium Dialysate

In this 68-year-old woman with malignancy-associated hypercalcemia refractory to aggressive saline hydration, loop diuretics, and denosumab, and with severe renal insufficiency (creatinine 3.4 mg/dL, CrCl ≈15-20 mL/min), hemodialysis using calcium-free or low-calcium dialysate (1.25-1.50 mmol/L) is the next appropriate treatment. 1, 2

Rationale for Dialysis in This Clinical Context

Renal replacement therapy is specifically indicated when severe hypercalcemia persists despite standard medical therapy in the setting of oliguric acute kidney injury or severe renal impairment. 2 This patient has exhausted first-line (saline, diuretics) and second-line (denosumab) therapies, and her renal function is critically impaired at stage 5 chronic kidney disease. 1, 2

Why Dialysis Works

• Intermittent hemodialysis provides rapid calcium removal with clearance rates of approximately 70-100 mL/min, making it highly effective for urgent correction. 2
• The use of calcium-free or low-calcium dialysate (1.25-1.50 mmol/L or 1.5-2.0 mEq/L) creates a concentration gradient that drives calcium removal from the bloodstream. 1, 2, 3
• Hemodialysis is particularly effective when hypercalcemia is complicated by renal insufficiency or anuria, as in this case. 1, 3

Alternative Considerations That Are Less Appropriate

While other options exist, they are less suitable for this specific patient:

• Repeat denosumab dosing: The patient has already received a full dose of denosumab without response, and there is no established evidence for immediate repeat dosing in refractory cases. 1
• Calcitonin: Provides only rapid but transient benefit (1-4 hours) with limited efficacy and tachyphylaxis ("escape phenomenon"), making it unsuitable as definitive therapy. 3, 4, 5
• Corticosteroids: Only effective for specific etiologies (lymphoma, multiple myeloma, granulomatous disease, vitamin D intoxication), not for solid tumor-associated hypercalcemia. 1, 3
• Gallium nitrate: Contraindicated in severe renal impairment due to nephrotoxicity. 4, 6

Dialysis Protocol and Monitoring

Dialysis Parameters

• Use calcium-free or low-calcium dialysate with calcium concentration of 1.25-1.50 mmol/L (1.5-2.0 mEq/L). 1, 2
• Continuous renal replacement therapy (CRRT) may be preferred if the patient is hemodynamically unstable, though intermittent hemodialysis provides more rapid calcium removal. 2

Critical Monitoring Requirements

• Measure ionized calcium every 4-6 hours during the first 48-72 hours, then twice daily until stable. 1, 3
• Monitor serum calcium, renal function, and electrolytes (especially potassium and magnesium) every 6-12 hours during the acute phase. 2, 3
• Assess for rebound hypercalcemia after dialysis, which may require repeated treatments. 2
• Evaluate ECG changes, particularly QT interval prolongation, in patients with severe hypercalcemia. 2, 3

Important Caveats and Pitfalls

Do Not Delay Dialysis

• Do not delay initiation of renal replacement therapy in patients with severe symptomatic hypercalcemia and renal insufficiency. 2 This patient has already failed medical management and has critical renal impairment.

Concurrent Supportive Measures

• Continue aggressive hydration to maintain diuresis if urine output permits, though this may be limited by the patient's renal function. 1, 2
• Discontinue all calcium-containing medications, calcium-based phosphate binders, and vitamin D supplements immediately. 2, 3
• Avoid nephrotoxic agents including NSAIDs and intravenous contrast media to prevent further renal deterioration. 3

Prognosis and Underlying Malignancy

• Hypercalcemia of malignancy carries a poor prognosis with median survival of approximately 1 month in some studies. 1
• Treating the underlying cancer remains fundamental for long-term calcium control, though this may not be feasible given the severity of presentation. 1, 3

Post-Dialysis Management

• After calcium normalization with dialysis, consider whether the patient can be transitioned back to denosumab or whether continued dialysis will be required for calcium control. 1
• Perform a baseline dental examination if not already done, as the patient may require ongoing bone-modifying therapy. 1, 2
• Monitor for hypocalcemia after aggressive dialysis, though symptomatic hypocalcemia is uncommon and only requires treatment if tetany or seizures occur. 3